Barinthus Biotherapeutics (BRNS) Earnings Date & Reports

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

BRNS is expected to report earnings to fall 3.85% to -25 cents per share on November 05

Barinthus Biotherapeutics BRNS Stock Earnings Reports

Q3'26

Est.

$-0.25

Q2'26

Beat

by $0.02

Q1'26

Beat

by $0.18

Q4'25

Beat

by $0.11

Q3'25

Beat

by $0.04

The last earnings report on August 06 showed earnings per share of -25 cents, beating the estimate of -28 cents. With 241.54K shares outstanding, the current market capitalization sits at 30.23M.

View a ticker or compare two or three

BRNS

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for BRNS